Illuminating Pathways in Epithelial-Driven Inflammation

Program Description

Join us for a dynamic Mechanisms to Medicine symposium featuring expert panelists Drs. Joseph Han, Flavia Hoyte, and Nizar Jarjour as they examine evolving management approaches for epithelial cytokine–driven inflammatory diseases of the upper and lower airways. This program brings together multidisciplinary perspectives from pulmonology, allergy and immunology, and otorhinolaryngology to explore shared underlying disease mechanisms in asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). 

The engaging faculty panel will guide participants through an examination of epithelial cytokine signaling in airway diseases and practical therapeutic decision-making involving new and emerging biologic therapies that target these shared upstream mechanisms. Through a focused Whiteboard animation, case-based checkpoints, and interactive faculty dialogue, learners will examine how epithelial alarmins such as thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33) drive inflammation, airway dysfunction, and disease persistence. 

Attendees will also learn about the latest clinical evidence for newer and emerging biologic therapies that target upstream epithelial cytokine signaling and discuss how to incorporate these novel therapies into mechanism-based treatment strategies, with an emphasis on optimizing disease control, reducing oral corticosteroid use, and improving outcomes across the unified airway.

Target Audience

This educational activity has been designed to educate pulmonologists, clinical immunologists/allergists, and ear, nose, and throat [ENT] specialists who manage patients with epithelial-driven inflammatory airway diseases.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Explain the pathogenesis of epithelial-driven inflammatory airway diseases, including implications for the treatment of asthma, CRSwNP, and COPD
2. Discuss the clinical profiles and evidence for biologic therapies that target epithelial cytokines in the treatment of epithelial-driven inflammatory airway diseases
3. Incorporate biologic medications into therapeutic regimens for epithelial-driven inflammatory airway diseases to address underlying pathophysiologic processes, improve disease control, and reduce oral corticosteroid use

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Joseph Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Sanofi, Teva Pharmaceutical Industries Ltd.; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc; Stock Shareholder: Amgen

Nizar Jarjour, MD, ATSF: Consulting fees: AstraZeneca plc, Chiesi, General Medicines, and GSK plc

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.